XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Cumulative Effect Adjustment
Additional paid-in capital
Accumulated other comprehensive (loss) income
Accumulated deficit
Cumulative Effect Adjustment
Accumulated deficit
Cumulative Effect Adjustment
Total
Balance (in shares) at Dec. 31, 2020 69,718,096              
Balance at the beginning of the period at Dec. 31, 2020 $ 70 $ (175,236) $ 2,171,746 $ (60,957) $ 54,796 $ (1,628,877) $ (120,440) $ 481,982
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 635,871              
Exercise of options $ 1   17,308         17,309
Restricted stock vesting and issuance (in shares) 307,658              
Issuance of common stock in connection with an employee stock purchase plan (in shares) 166,601              
Issuance of common stock in connection with an employee stock purchase plan     5,792         5,792
Share-based compensation expense     103,513         103,513
Receivable from investor     483         483
Other           25   25
Net Income (Loss)           (523,901)   (523,901)
Comprehensive income       36,675       36,675
Balance (in shares) at Dec. 31, 2021 70,828,226              
Balance at the end of the period at Dec. 31, 2021 $ 71   2,123,606 (24,282)   (2,097,957)   1,438
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock related to stock purchase agreement (in shares) 1,095,290              
Issuance of common stock related to stock purchase agreement $ 1   49,999         50,000
Exercise of options (in shares) 496,863              
Exercise of options     14,632         14,632
Restricted stock vesting and issuance (in shares) 490,008              
Issuance of common stock in connection with an employee stock purchase plan (in shares) 194,305              
Issuance of common stock in connection with an employee stock purchase plan     6,450         6,450
Share-based compensation expense     110,333         110,333
Net Income (Loss)           (559,017)   (559,017)
Comprehensive income       29,078       29,078
Balance (in shares) at Dec. 31, 2022 73,104,692              
Balance at the end of the period at Dec. 31, 2022 $ 72   2,305,020 4,796   (2,656,974)   (347,086)
Increase (Decrease) in Stockholders' Equity                
Exercise of options (in shares) 822,482              
Exercise of options $ 1   24,039         24,040
Restricted stock vesting and issuance (in shares) 915,203              
Restricted stock vesting and issuance, net $ 1             1
Issuance of common stock in connection with an employee stock purchase plan (in shares) 209,050              
Issuance of common stock in connection with an employee stock purchase plan     5,954         5,954
Issuance of common stock in connection with a milestone payable (in shares) 657,462              
Issuance of common stock in connection with a milestone payable $ 1   29,569         29,570
Share-based compensation expense     101,636         101,636
Receivable from investor     15         15
Net Income (Loss)           (626,604)   (626,604)
Comprehensive income       (6,081)       (6,081)
Balance (in shares) at Dec. 31, 2023 75,708,889              
Balance at the end of the period at Dec. 31, 2023 $ 75   $ 2,466,233 $ (1,285)   $ (3,283,578)   $ (818,555)